Low vs. High-Dose Proton Pump Inhibitor in the Prevention of Bleeding after Endoscopic Submucosal Dissection: A Multicenter, Non-Inferiority, Randomized, Controlled Clinical Trial

2020 ◽  
Author(s):  
Li Yang ◽  
Jian Qi ◽  
Weiqing Chen ◽  
Qinghong Guo ◽  
Rui Xie ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Proton Pump Inhibitor ◽  
Endoscopic Submucosal Dissection ◽  
Proton Pump ◽  
Controlled Clinical Trial ◽  
High Dose ◽  
Randomized Controlled Clinical Trial ◽  
Randomized Controlled ◽  
Submucosal Dissection

scholarly journals High-dose intravenous versus oral iron in blood donors with iron deficiency: The IronWoMan randomized, controlled clinical trial

2020 ◽  
Vol 39 (3) ◽  
pp. 737-745 ◽  
Author(s):  
Camilla Drexler ◽  
Susanne Macher ◽  
Ines Lindenau ◽  
Magdalena Holter ◽  
Martina Moritz ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Iron Deficiency ◽  
Blood Donors ◽  
Oral Iron ◽  
Controlled Clinical Trial ◽  
High Dose ◽  
Randomized Controlled Clinical Trial ◽  
Randomized Controlled

An open-label, randomized, controlled clinical trial to explore the curative effects between the treatment of capecitabine and andrographolide and the single capecitabine in the patients with pathological and/or histologic diagnosed unresectable, advanced, recurrent, and metastatic colorectal cancer.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. TPS819-TPS819 ◽  
Author(s):  
Yongqian Shu ◽  
Jing Sun ◽  
Peifen Cai ◽  
Weicheng Wang ◽  
Xiao Han ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trial ◽  
Target Therapy ◽  
The Elderly ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
High Dose ◽  
Randomized Controlled Clinical Trial ◽  
Open Label ◽  
Randomized Controlled

TPS819 Background: Colorectal cancer (CRC) is one of the most commonly diagnosed solid tumors worldwide. Current therapies for the treatment of CRC mainly comprise fluoropyromidine-based chemotherapies that are used individually or in combination with oxaliplatin or/with target therapy. Andrographolide, a natural diterpenoid from Andrographispaniculata, has been reported to exert antibacterial, antiviral, anti-inflammation and neuroprotectiveactivities. Our previous studies have proved that Andrographolide can inhibit tumor growth in mice at a relatively high dose(about 200 mg/kg).The aim of the study is to make a comparison of PFS, RR, and OS of the elderly CRC between the treatment of xeloda and andrographolide and the signal xeloda.We look forward to these findings highlight the potential possibility of using this natural, safe and relatively inexpensivecompound as potential adjunctive treatments in improving the overall treatment response of patients with CRC in future. Methods: This is an open-label, randomized, controlled clinical trial. Patients older than or equal to 65, by pathological and/or histologic diagnosed unresectable, advanced, recurrent andmetastatic CRC, will be enrolled. These patients’ tumors must be clearly measured by radiographic technology. All cases of chemotherapy patients randomly divided into two groups, experimental group (xeloda with andrographolide): xeloda: 1250mg/m2 , po bid, d1–14, q3w; andrographolide: 500mg, ivd qd, d1–14, q3w; control group (xeloda): 1250mg/m2, po bid, d1–14, q3w, 21d/cycle. After each 2 cycles, patients will be examined by imageological tests (CT and/or MRI) or tumour biomarkers (CEA and CA199) to estimate the curative effects. Until the tumor progression or after 6 cycles, patients will be removed from this study. PFS is set as the primary endpoint while secondary endpoints include overall survival (OS), overall response rate (ORR), and health-related quality of life (HRQoL). Recruitment has begun in Jan 2014 and about 52 patients has joined this study. Clinical trial information: NCT01993472.

Sign in / Sign up

Export Citation Format

Share Document